Further, no variation of HLA-DRα was detected in lysates isolated from the Daudi Burkitt’s lymphoma cells treated with the zVAD-fmk pancaspase inhibitor for 72 h, indicating that proteolytic activity of caspase-2, or of other caspases, does not interfere with HLA expression (Fig. 5d). This evidence concerns the gene CASP2 and Burkitt lymphoma.